Note that the problem wasn't that they didn't include women in the trials, the problem is the trial design itself - they didn't consider trialing lower dosages for women. Also note that age makes a huge difference in dosage as well, with elderly people often needing half the dose of some drugs (eg antidepressants).
The point is that it isn't the numbers of women in the trial that is the problem, it is the design of the trial eg not listening to women that the dosage is too high that is the problem.
It's a systematic problem of "evidence based medicine" where trials are just designed to get approval rather than optimized for the best patient experience (which costs more money)